Axogen (AXGN) As Russell Index Removal Tests A Narrative Of Undervaluation

Axogen (AXGN) has been removed from several Russell indexes, including the Russell Microcap Index and Russell 3000E Index. This change can reshape trading patterns as index funds and passive vehicles rebalance their holdings.

See our latest analysis for Axogen.

Against the backdrop of these index removals, Axogen’s recent trading has been mixed in the very short term but strong over longer periods. The company has a 1-day share price return of 2.04% and a 90-day share price return of 36.48%, while the 1-year total shareholder return is 261.99%, pointing to momentum that has been building rather than fading.

If you are reassessing your exposure to Axogen after the index changes, it can be useful to compare it with other potential opportunities and see how it stacks up beside 40 healthcare AI stocks.

Axogen now trades about 16% below the average analyst price target after a very strong 1-year return and index removals, so this discount may either represent an opportunity or indicate that the market’s caution about its losses is reasonable.

Most Popular Narrative: 14.1% Undervalued

On the most followed narrative, Axogen’s fair value of $50.78 sits above the last close at $43.62, setting up a valuation gap tied directly to long term growth, margins and discount rate assumptions.

Broad-based adoption of Axogen's nerve care algorithm across multiple markets (extremities, oral maxillofacial, breast) and exceptional momentum in activating high-potential accounts signal that the addressable market for nerve repair is still substantially underpenetrated, suggesting a long runway for sustained double-digit revenue growth as awareness and adoption rise.

Read the complete narrative. Read the complete narrative.

Want to understand why Axogen is priced for meaningful expansion in sales and a swing from losses to profits, all under a tightly defined discount rate and earnings path? The key ingredients are revenue growth assumptions, margin uplift and a future profit multiple that needs serious conviction to accept. Curious which specific profitability and revenue milestones this narrative leans on, and how sensitive that $50.78 fair value is to even small changes in those inputs?

Result: Fair Value of $50.78 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this Axogen narrative can quickly be tested if the FDA Biologics License Application timeline slips, or if reimbursement or pricing for Avance Nerve Graft tightens.

Find out about the key risks to this Axogen narrative.

Another View: What Multiples Say About Axogen

While the most popular Axogen narrative leans on long term growth assumptions to support a fair value of $50.78, current trading tells a tougher story. The stock sits on a P/S of 9.7x, compared with 2.9x for the US Medical Equipment industry, 8.9x for peers, and a fair ratio of 4.8x, which signals meaningful valuation risk if sentiment cools or growth underwhelms. Which lens do you trust more when expectations are this high?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mix of enthusiasm and caution around Axogen leaves you uncertain, act while the numbers are fresh and weigh both sides using the 1 key reward and 2 important warning signs 1 key reward and 2 important warning signs

Looking for more investment ideas beyond Axogen?

If Axogen has you rethinking your portfolio, now is a good moment to widen the lens and compare it with other focused opportunities using the Simply Wall Street Screener.

• Target potential mispricings by scanning for companies that combine strong fundamentals with attractive valuations through the 44 high quality undervalued stocks.
• Strengthen your downside protection by filtering for companies with robust finances using the solid balance sheet and fundamentals stocks screener (47 results).
• Spot future standouts early by reviewing the screener containing 19 high quality undiscovered gems before they gain broader attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com